SCHEMBL13816305

SCHEMBL13816305

CCNC(=O)c1ccc(Sc2ccc(CC(=O)OC)cc2)c(N)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.56
▸ TP53 P04637 6/20 0.56
▸ LMNA P02545 8/20 0.52
▸ ALDH1A1 P00352 5/20 0.52
▸ HPGD P15428 5/20 0.52
▸ KDM4E B2RXH2 4/20 0.52
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.51
▸ GAA P10253 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ SMN1; SMN2 Q16637 5/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13816308 0.83 MAPT (0.56) MAPTLMNAALDH1A1KDM4EGAA
SCHEMBL13816306 0.75 PTGDR2 (0.71) PTGDRPTGDR2
SCHEMBL13816512 0.74 PTGDR2 (0.48) MAPTTP53LMNAALDH1A1L3MBTL1
SCHEMBL13816489 0.73 LMNA (0.44) MAPTTP53LMNAALDH1A1L3MBTL1
SCHEMBL1454475 0.70 TP53 (0.53) MAPTTP53LMNAALDH1A1HPGD
SCHEMBL3098975 0.70 ALOX15 (0.55) MAPTLMNAALDH1A1HPGDKDM4E
SCHEMBL1453977 0.70 TP53 (0.57) MAPTTP53LMNAALDH1A1HPGD
SCHEMBL13816462 0.70 MAPT (0.48) MAPTLMNAALDH1A1HPGDKDM4E
SCHEMBL27348226 0.69 ALDH1A1 (0.69) MAPTTP53LMNAALDH1A1HPGD
SCHEMBL811455 0.69 MAPT (0.80) MAPTTP53LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541383-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2009-06-02 — — US disclosed
US-7541383-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2009-06-02 — — US disclosed
US-20080085891-A1 Asthma and allergic inflammation modulators FU ZICE 2008-04-10 — — US disclosed
US-20080085891-A1 Asthma and allergic inflammation modulators FU ZICE 2008-04-10 — — US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 — — US disclosed
US-7321001-B2 Asthma and allergic inflammation modulators AMGEN INC. (US) 2008-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085891-A1 Asthma and allergic inflammation modulators IL5, TSLP, CYSLTR2 MAPT 1718/4885TP53 491/4885LMNA 4770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback